NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Chandrakant Birla Acquires 39.89% Stake in BirlaNu via Inter-se Promoter Transfer
Mr. Chandrakant Birla, a lead promoter of BirlaNu Limited, has consolidated his holding by acquiring 30,07,836 equity shares (39.89% stake) through inter-se transfers. The transaction, executed on December 29, 2025, involved nine promoter group entities transferring their entire holdings to Mr. Birla at an average price of INR 1518.87 per share. While Mr. Birla's individual stake has risen from 0.68% to 40.57%, the total promoter group holding remains unchanged at 40.57%. This move is characterized as an internal restructuring exercise within the promoter group.
முக்கிய அம்சங்கள்
Acquisition of 30,07,836 shares representing 39.89% of the company's equity capital.Shares acquired at an average price of INR 1518.87 per share via off-market inter-se transfer.Major sellers include Central India Industries (18.65%) and Shekhavati Investments (7.38%).Chandrakant Birla's direct ownership increased significantly from 0.68% to 40.57%.Total promoter and promoter group shareholding remains constant at 40.57%.
👀 கவனிக்க வேண்டியவை
As this is an internal restructuring with no change in the aggregate promoter holding, it has no immediate impact on company fundamentals. Investors should view this as a consolidation of control under the primary promoter.
Biocon Shareholders Approve Fundraise and Preferential Share Issuance at EGM
Biocon Limited shareholders have approved all six resolutions proposed at the Extraordinary General Meeting held on December 31, 2025. Key approvals include raising funds through equity or other securities and a preferential issuance of shares for consideration other than cash. Shareholders also authorized an increase in investment and loan limits under Section 186 and cleared material related-party transactions with Mylan Inc. While most resolutions passed with near-unanimous support, the proposal to increase investment limits saw a notable 15.67% dissent from voting participants.
முக்கிய அம்சங்கள்
Approved raising funds in one or more tranches via equity or other securities with 99.13% majority support.Passed a special resolution for the issuance of equity shares on a preferential basis for non-cash consideration with 99.73% in favour.Authorized an increase in limits for investments, loans, and guarantees under Section 186 with 84.33% approval.Cleared material related-party transactions with Mylan Inc. with 99.19% of non-interested votes in favour.Total voting turnout for the meeting represented approximately 81% of the total share capital.
👀 கவனிக்க வேண்டியவை
Investors should monitor the upcoming details regarding the specific terms and pricing of the approved fundraise. The approval for preferential issuance and related-party transactions suggests strategic moves involving its subsidiary, Biocon Biologics.
Biocon EGM Approves Fundraise, Preferential Issue, and Mylan Related Party Transactions
Biocon Limited conducted an Extraordinary General Meeting on December 31, 2025, to pass six key resolutions focused on capital restructuring and growth. Shareholders voted on increasing the authorized share capital and raising fresh funds through equity or other securities in multiple tranches. A significant resolution involved the issuance of equity shares on a preferential basis for consideration other than cash, alongside approval for material related party transactions with Mylan Inc. These moves are designed to strengthen the balance sheet and support the strategic objectives of its subsidiary, Biocon Biologics.
முக்கிய அம்சங்கள்
Approval sought for increasing the Authorised Share Capital and amending the Memorandum of Association.Proposed raising of funds in one or more tranches through issuance of equity shares or other securities.Issuance of Equity Shares on a preferential basis for consideration other than cash.Approval for material related party transactions with Mylan Inc., a related party of Biocon Biologics.Increased limits for making investments, extending loans, and providing guarantees under Section 186.
👀 கவனிக்க வேண்டியவை
Investors should monitor the specific terms of the fundraise and the identity of the preferential allottees to assess potential dilution. The non-cash preferential issue and Mylan transaction suggest a strategic settlement or asset acquisition that could impact long-term valuation.
ESAB India Board Meeting on Feb 10 to Consider Q3 Results and Second Interim Dividend
ESAB India Limited has scheduled a Board Meeting for February 10, 2026, to approve the unaudited financial results for the quarter ended December 31, 2025. Crucially, the board will also consider the recommendation of a second interim dividend for the financial year 2025-26. In accordance with SEBI regulations, the trading window for designated persons will remain closed from January 1, 2026, to February 12, 2026. This announcement provides investors with a clear timeline for upcoming financial performance data and potential income distributions.
முக்கிய அம்சங்கள்
Board meeting scheduled for February 10, 2026, to review Q3 FY26 results.Consideration of a second interim dividend for the financial year ending March 31, 2026.Trading window closure for insiders from January 1, 2026, to February 12, 2026.Results to be published in Business Standard and Makkal Kural newspapers.
👀 கவனிக்க வேண்டியவை
Investors should track the February 10 results for margin trends and dividend yield, as the company has a history of consistent payouts.
Panacea Biotec Receives ₹9.38 Crore Income Tax Penalty Demand
Panacea Biotec Limited has received three demand orders from the Income Tax Department totaling ₹9.38 Crore. The penalties are attributed to alleged under-reporting of income for Assessment Years 2017-18, 2020-21, and 2021-22. The company has declared the demand as not maintainable and intends to file an appeal with the appellate authority. While the company does not foresee an immediate operational impact, the final resolution of this litigation will determine the actual financial outflow.
முக்கிய அம்சங்கள்
Aggregate penalty demand of ₹9.38 Crore received from the Assistant Commissioner of Income Tax, Delhi.Specific demands include ₹5.55 Crore for AY 2017-18, ₹3.11 Crore for AY 2020-21, and ₹0.72 Crore for AY 2021-22.Penalties imposed under Section 270A of the Income Tax Act, 1961 for alleged under-reporting of income.Company plans to contest the orders by filing an appeal with the relevant appellate authority.
👀 கவனிக்க வேண்டியவை
Monitor the progress of the tax appeal as a negative outcome would result in a cash outflow of ₹9.38 Crore. No immediate action is required as the company is actively contesting the demand.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Panacea Biotec has received an amendment to its existing contract with UNICEF for the supply of its WHO pre-qualified Pentavalent vaccine, Easyfive-TT®. The total value of the award has been increased by approximately $8.93 million (around ₹80 Crore) for the years 2026 and 2027. Specifically, the 2026 allocation increased by $2.55 million, while the 2027 allocation saw a combined increase and additional award totaling $6.38 million. This development strengthens the company's long-term revenue visibility and reinforces its partnership with international health organizations.
முக்கிய அம்சங்கள்
Total contract value increased by $8.93 million (~₹80 Crore) for CY2026 and CY20272026 supply value increased by $2.55 million to a total of $16.8 million2027 supply value increased by $6.38 million through amendments and additional awardsSupplies involve the WHO pre-qualified fully liquid Pentavalent vaccine, Easyfive-TT®The contract is with an international entity (UNICEF), ensuring high credit quality
👀 கவனிக்க வேண்டியவை
This order provides strong revenue visibility for the next two years and validates the company's standing in the global vaccine market. Investors should monitor the impact on margins and the company's ability to scale production to meet these increased requirements.
Birla Corp Shareholders Approve New Articles of Association Amid Legal Stay
Birla Corporation's shareholders have approved the adoption of a new set of Articles of Association (AoA) at the adjourned 105th AGM held on December 22, 2025. The update aims to align the company's governance framework with the Companies Act 2013 and current SEBI regulations, replacing outdated provisions from the 1956 Act. However, the Calcutta High Court has ordered that the amended AoA shall not take effect for at least one month, pending the disposal of miscellaneous appeals. The final implementation remains contingent on the outcome of these legal proceedings.
முக்கிய அம்சங்கள்
Shareholders approved the adoption of a new set of Articles of Association via a Special Resolution at the adjourned 105th AGM.The Calcutta High Court has directed that the amended AoA shall not take effect for at least 30 days from December 22, 2025.The 105th AGM was originally convened on September 15, 2025, and adjourned sine die regarding this specific agenda item.The governance update is intended to replace redundant articles and align with the Companies Act, 2013 and SEBI LODR regulations.Implementation of the voting results and subsequent steps are subject to the final outcome of pending Miscellaneous Appeals.
👀 கவனிக்க வேண்டியவை
Investors should monitor the resolution of the legal appeals over the next month as the stay indicates potential friction in governance changes. While the update is a standard regulatory alignment, the court's intervention makes it a key monitoring point for corporate governance.
Calcutta HC Dismisses Promoter Pleas; Birla Corp to Publish Voting Results on Amended AoA
The Calcutta High Court has dismissed two revisional applications filed by five promoter shareholders against Birla Corporation regarding the amendment of its Articles of Association. The court has permitted the company to publish the voting results for Resolution No. 5, which pertains to these amendments. However, the court mandated a one-month stay on implementing the changes if passed, during which time the lower appeal court must resolve pending Miscellaneous Appeals (No. 303 and 360 of 2025). This development indicates a procedural step forward for the company in a long-standing legal battle involving promoter groups.
முக்கிய அம்சங்கள்
Calcutta High Court dismissed Civil Revisional Applications C.O. No. 4320 and 4338 of 2025 on December 22, 2025.Company authorized to publish voting results for Resolution No. 5 regarding the adoption of amended Articles of Association.Implementation of amended AoA is stayed for one month to allow the lower court to dispose of Misc. Appeal Nos. 303 and 360 of 2025.The final validity of the voting and subsequent steps remains subject to the outcome of the pending Miscellaneous Appeals.
👀 கவனிக்க வேண்டியவை
Investors should monitor the publication of the voting results and the subsequent ruling of the appeal court within the next 30 days. The outcome will determine the company's governance structure and the resolution of internal promoter disputes.
Biocon Biologics Secures Full Global Rights for Biosimilar Adalimumab (Hulio)
Biocon Biologics has expanded its agreement with Fujifilm Kyowa Kirin Biologics (FKB) to secure full and exclusive global rights for Hulio (biosimilar Adalimumab). This strategic move transitions Biocon from a commercialization-only partner to an end-to-end owner responsible for manufacturing, development, and commercialization. While Biocon will pay license fees and royalties, FKB will offset certain development costs, which is expected to enhance cost efficiency and operational flexibility. This integration strengthens Biocon's immunology portfolio, which currently serves over 6.3 million patients across 120+ countries.
முக்கிய அம்சங்கள்
Acquisition of full global rights for manufacturing and commercialization of biosimilar Adalimumab (Hulio).Transition from a commercialization-only model to an end-to-end integrated model for the product.FKB to offset certain development costs while Biocon pays technology license fees and royalties.Strategic focus on the immunology portfolio, which currently includes three major biosimilars.Commercial production at Biocon facilities to commence following technology transfer and regulatory approvals.
👀 கவனிக்க வேண்டியவை
This vertical integration is a margin-accretive move that provides Biocon with greater control over its supply chain and product development. Investors should monitor the timeline for technology transfer and regulatory approvals for the in-house manufacturing of Hulio.
Biocon Limited has successfully issued Commercial Papers (CP) worth Rs 1,800 Crores on a private placement basis. The short-term debt instrument carries a competitive interest rate of 6.85% and has a tenure of 88 days, maturing on March 20, 2026. The issue has been subscribed by major institutional investors including SBI Mutual Fund, Axis Mutual Fund, and Aditya Birla Sun Life. The high credit rating of IND A1+ underscores the company's strong short-term credit profile.
முக்கிய அம்சங்கள்
Total issue size of Rs 1,800 Crores via private placement to mutual fundsShort-term tenure of 88 days with maturity scheduled for March 20, 2026Competitive coupon rate of 6.85% per annumAssigned a top-tier credit rating of IND A1+ by India RatingsProposed to be listed on the National Stock Exchange (NSE)
👀 கவனிக்க வேண்டியவை
Investors should view this as a routine short-term liquidity management exercise. The low interest rate and high credit rating indicate strong market confidence in Biocon's financial stability.
Birla Corp Re-convenes Adjourned 105th AGM to Vote on New Articles of Association
Birla Corporation Limited successfully conducted its adjourned 105th Annual General Meeting on December 22, 2025, to address the pending adoption of a new set of Articles of Association. The meeting was previously delayed due to a court injunction, which has since been stayed by the Additional District & Sessions Judge. A total of 477 members attended the meeting, and remote e-voting was conducted between December 19 and December 21, 2025. The final voting results are expected to be disclosed within two working days.
முக்கிய அம்சங்கள்
Adjourned 105th AGM re-convened on Dec 22, 2025, specifically for Item No. 5 regarding new Articles of Association.The meeting followed a stay order dated Nov 21, 2025, which lifted a previous injunction against the vote.Remote e-voting was open for shareholders from Dec 19 (9:00 AM) to Dec 21 (5:00 PM), 2025.A total of 477 members were present in person or through proxy at the Kolkata venue.Consolidated voting results and the Scrutinizer's Report will be announced within 2 working days.
👀 கவனிக்க வேண்டியவை
Investors should monitor the upcoming disclosure of the voting results to confirm the adoption of the new Articles of Association. The resolution of this legal hurdle allows the company to move forward with its updated governance framework.
MobiKwik Seeks Shareholder Nod for Appointment of Radhakrishna Nair as Independent Director
One MobiKwik Systems has issued a postal ballot notice to seek shareholder approval for the appointment of Mr. Radhakrishna Nair as a Non-Executive Independent Director. The proposed term is for five years, effective from December 17, 2025, to December 16, 2030. The resolution includes a proposed annual remuneration of ₹17,00,000 for the director. Shareholders can cast their votes through a remote e-voting process that concludes on January 21, 2026.
முக்கிய அம்சங்கள்
Appointment of Mr. Radhakrishna Nair for a 5-year term starting December 17, 2025.Proposed annual remuneration of ₹17,00,000 plus reimbursement of incidental expenses.Remote e-voting period runs from December 23, 2025, to January 21, 2026.Cut-off date for determining shareholder voting eligibility was December 19, 2025.Special resolution includes approval for the director to continue serving beyond the age of 75 years.
👀 கவனிக்க வேண்டியவை
Shareholders should review the appointee's credentials and participate in the e-voting process before the January 21, 2026 deadline. This is a routine governance matter and does not require immediate changes to investment positions.
Chandrakant Birla to Acquire 39.89% Stake in BirlaNu via Inter-se Promoter Transfer
Mr. Chandrakant Birla, a promoter of BirlaNu Limited, is set to acquire 30,07,836 equity shares, representing 39.89% of the company's share capital. This transaction is an inter-se transfer from nine other promoter group entities as part of an internal restructuring exercise. The acquisition is expected to take place on or after December 29, 2025, at a price within the SEBI-prescribed range. Post-acquisition, Mr. Birla's direct stake will rise significantly from 0.68% to 40.57%, though the overall promoter group holding remains unchanged.
முக்கிய அம்சங்கள்
Acquisition of 30,07,836 equity shares representing 39.89% of total share capitalInter-se transfer among 9 promoter group entities to Mr. Chandrakant BirlaAcquirer's direct holding to increase from 0.68% to 40.57% post-transactionTransaction price based on 60-day VWAP of INR 1,770.94 per shareInternal restructuring with no change in total promoter group shareholding
👀 கவனிக்க வேண்டியவை
This is a routine internal restructuring within the promoter group and does not impact the company's operations or total promoter stake. Investors should treat this as a neutral event with no immediate action required.
Birla Corp Shareholders Reject Appointment of Sudeep Roy as Director; 65.2% Votes Against
Birla Corporation has released the long-delayed voting results for the appointment of Mr. Sudeep Roy as a Non-Executive Non-Independent Director, following a Calcutta High Court order. The special resolution was decisively defeated, with 65.21% of total votes cast against the appointment. Notably, significant opposition came from the promoter group itself (66.14% against) and public institutions (60.28% against), indicating a major lack of consensus on board composition.
முக்கிய அம்சங்கள்
Special resolution to appoint Mr. Sudeep Roy failed with only 34.79% votes in favour.A total of 3.57 crore votes (65.21%) were cast against the resolution.Promoter group showed internal division, with 66.14% of their polled votes (2.49 crore shares) against the appointment.Public institutional investors also rejected the move, with 60.28% of their votes cast against.The results were released after a two-year delay following the disposal of a legal case (GA/1/2023) by the Calcutta High Court.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company for signs of promoter-level conflict or corporate governance issues, as the high 'Against' vote from promoters is unusual. No immediate action is required, but the lack of board consensus warrants a cautious outlook on management stability.
Biocon Receives US FDA EIR with VAI Status for New Jersey Generics Facility
Biocon Limited has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (US FDA) for its Biocon Generics Inc facility in Cranbury, New Jersey. The inspection, which took place from October 6 to October 10, 2025, resulted in a 'Voluntary Action Indicated' (VAI) status. A VAI status indicates that while some objectionable conditions were observed, the agency is not recommending any administrative or regulatory action at this time. This outcome is positive as it signifies the facility is in a state of acceptable compliance for the U.S. market.
முக்கிய அம்சங்கள்
US FDA issued an Establishment Inspection Report (EIR) for the Cranbury, New Jersey facility.The inspection was conducted over a 5-day period from October 6 to October 10, 2025.The facility received a 'Voluntary Action Indicated' (VAI) classification, avoiding more severe regulatory sanctions.The EIR marks the formal closure of the inspection cycle for this specific U.S.-based manufacturing site.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive regulatory development that reduces compliance risk for Biocon's U.S. operations. This clearance supports the company's ability to maintain supply and seek new product approvals from this facility.
A B Infrabuild Secures ₹52.08 Crore Railway Project for Road Over Bridge Construction
A B Infrabuild Limited has received a Letter of Acceptance from East Coast Railways for a significant infrastructure project. The contract involves the construction of a Road Over Bridge (ROB) on the HWH-VSKP main line under the Khurdha Road division. Valued at approximately ₹52.08 Crores, the project is scheduled to be completed within a 24-month timeframe. This order strengthens the company's presence in the railway infrastructure sector and adds to its revenue visibility.
முக்கிய அம்சங்கள்
Awarded a domestic contract worth ₹52,08,33,449.63 from East Coast Railways.Project involves construction of a Road Over Bridge (ROB) with composite and T-Beam girders.The execution period for the entire project is set at 24 months.The contract was secured through a competitive tender process with no promoter interest involved.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development for the company's order book and monitor the execution progress over the next 24 months. The company's ability to secure and deliver on Indian Railways projects is a key driver for its long-term valuation.
Bigbloc Construction H1 FY26: Capacity Hits 1.3M CBM; 5-Year Revenue CAGR at 21.5%
Bigbloc Construction has successfully expanded its AAC block capacity to 1.3 million CBM per annum, achieving a 21.5% revenue CAGR over the last five years. The company reported FY25 revenue of INR 2,246 million and is diversifying into construction chemicals and wall panels via a JV with Thailand's SCG International. Despite lower FY25 return ratios (ROE 2.1%) due to heavy expansion capex, the company maintains a competitive <2% rejection rate and generates carbon credits. Future growth is anchored by a new greenfield project in Madhya Pradesh and potential entry into South Indian markets.
முக்கிய அம்சங்கள்
Total manufacturing capacity increased to 13,00,000 CBM P.A. as of FY2025 from 5,75,000 in FY2022.Maintained a 5-year Revenue CAGR of 21.5% and EBITDA CAGR of 24.6% as of FY2025.Operational efficiency highlighted by a rejection rate of <2% compared to the 4-7% industry average.Strategic JV with SCG International for AAC wall panels and expansion into construction chemicals like tile adhesives.Planned greenfield expansion in Madhya Pradesh with 200,000 CBM capacity, expandable to 500,000 CBM.
👀 கவனிக்க வேண்டியவை
Investors should monitor the capacity utilization of the newly commissioned Wada and Ramosadi plants and the scale-up of the high-margin construction chemicals segment. The company is a strong play on green building materials, though current return ratios reflect a heavy investment phase.
Concord Biotech Appoints Raviraj Karia as CFO; Brings 23+ Years of Pharma Experience
Concord Biotech has appointed Mr. Raviraj Karia as its new Chief Financial Officer, effective December 18, 2025. Mr. Karia is a Chartered Accountant with over 23 years of experience in the pharmaceutical and healthcare sectors, having held leadership roles at Intas Pharmaceuticals and Claris Lifesciences. His expertise spans multi-billion dollar financing, large-scale M&A, and cost-efficiency programs. This strategic appointment is aimed at strengthening the company's financial discipline and governance as it scales.
முக்கிய அம்சங்கள்
Appointment of Mr. Raviraj Karia as CFO and Key Managerial Personnel effective December 18, 2025Brings over 23 years of experience in pharmaceuticals, healthcare, and private equity sectorsPreviously managed multi-billion dollar financing programs and led major outbound pharma acquisitionsProven track record of reducing borrowing costs by 2-3% annually through financial optimizationExpertise in implementing digital tools like SAP-based MIS and Power BI for financial governance
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive move for corporate governance and financial strategy. Monitor the company's future capital allocation and cost-efficiency metrics under the new leadership.
MobiKwik Appoints Navdeep Singh Suri as Board Chair; Separates Chair and Executive Roles
One MobiKwik Systems has appointed Navdeep Singh Suri, an Independent Director since 2021 and former diplomat, as the new Chairperson of its Board. This strategic move separates the Chairperson's role from executive management, as he succeeds Co-Founder and CFO Upasana Taku. The company currently commands a 19% market share in India's PPI wallet gross transaction value (GTV) as of September 2025. With a massive base of 183.5 million registered users and 4.71 million merchants, this transition is aimed at enhancing corporate governance and institutional maturity.
முக்கிய அம்சங்கள்
Navdeep Singh Suri appointed as Board Chairperson, having served as an Independent Director since 2021.The appointment separates the Board Chair role from executive management, succeeding Co-Founder Upasana Taku.MobiKwik holds a 19% market share of the PPI wallet gross transaction value (GTV) as of September 2025.The company reports a user base of over 183.5 million registered users and 4.71 million merchants.Mr. Suri brings extensive governance experience from the Indian Foreign Service and roles at SBI Funds International.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive governance milestone that aligns the company with global best practices by separating board oversight from executive functions. Monitor the company's ability to leverage this institutional maturity to further scale its 19% market share in the digital wallet space.
SBI Extends Tenure of Managing Director Ashwini Kumar Tewari Until December 2027
The Government of India has officially re-appointed Shri Ashwini Kumar Tewari as the Managing Director of State Bank of India. His current term was scheduled to conclude on January 27, 2026. The new extension ensures his leadership continues until his superannuation on December 31, 2027, or until further orders. This move provides significant leadership continuity for India's largest public sector lender during a critical period of credit growth.
முக்கிய அம்சங்கள்
Shri Ashwini Kumar Tewari re-appointed as Managing Director of State Bank of IndiaExtension granted beyond the current term ending January 27, 2026New tenure valid until superannuation date of December 31, 2027Notification issued by the Department of Financial Services, Ministry of Finance
👀 கவனிக்க வேண்டியவை
Investors should welcome this continuity in top management as it ensures stability in the bank's strategic direction. No immediate portfolio changes are necessary based on this administrative update.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
